Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s traded shares stood at 5.09 million during the last session, with the company’s beta value hitting 0.87. At the close of trading, the stock’s price was $17.90, to imply a decrease of -1.92% or -$0.35 in intraday trading. The TEVA share’s 52-week high remains $19.08, putting it -6.59% down since that peak but still an impressive 54.75% since price per share fell to its 52-week low of $8.10. The company has a valuation of $20.28B, with an average of 4.91 million shares in intraday trading volume over the past 10 days and average of 7.38 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Teva- Pharmaceutical Industries Ltd. ADR (TEVA), translating to a mean rating of 1.82. Of 8 analyst(s) looking at the stock, 1 analyst(s) give TEVA a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.66.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
After registering a -1.92% downside in the last session, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has traded red over the past five days. The 5-day price performance for the stock is -0.28%, and 0.90% over 30 days. With these gigs, the year-to-date price performance is 71.46%. Short interest in Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) saw shorts transact 24.49 million shares and set a 3.25 days time to cover.
The extremes give us $10 and $26 for target low and target high price respectively. As such, TEVA has been trading -45.25% off suggested target high and 44.13% from its likely low.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
Looking at statistics comparing Teva- Pharmaceutical Industries Ltd. ADR share performance against respective industry, we note that the company has underperformed competitors. Teva- Pharmaceutical Industries Ltd. ADR (TEVA) shares are 29.62% up over the last 6 months, with its year-to-date growth rate lower than industry average at -4.69% against 21.40%. Revenue is forecast to grow 10.00% this quarter before falling -28.00% for the next one. The rating firms project that company’s revenue will grow 2.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 4.12B. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 4.16B.Earnings reports from the last fiscal year show that sales brought in 3.85B and 4.46B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 7.00% before dropping -6.70% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 26.63% for the past 5-year period. While 2024 is set for a -4.19% return in earnings, projections for the next 5 years are at 0.47% annually.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. The company’s average dividend yield trailing the past 5-year period is 2.95%.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Teva- Pharmaceutical Industries Ltd. ADR insiders hold 0.00% of total outstanding shares, with institutional holders owning 54.92% of the shares at 54.92% float percentage. In total, 54.92% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 42.99 million shares (or 3.8279% of shares), all amounting to roughly $698.55 million.
The next major institution holding the largest number of shares is FMR LLC with 41.98 million shares, or about 3.7381% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $682.15 million.
